JPWO2023186015A5 - - Google Patents

Info

Publication number
JPWO2023186015A5
JPWO2023186015A5 JP2024554214A JP2024554214A JPWO2023186015A5 JP WO2023186015 A5 JPWO2023186015 A5 JP WO2023186015A5 JP 2024554214 A JP2024554214 A JP 2024554214A JP 2024554214 A JP2024554214 A JP 2024554214A JP WO2023186015 A5 JPWO2023186015 A5 JP WO2023186015A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
pharmaceutically acceptable
conjugate according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510606A (ja
JP2025510606A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/085097 external-priority patent/WO2023186015A1/zh
Publication of JP2025510606A publication Critical patent/JP2025510606A/ja
Publication of JP2025510606A5 publication Critical patent/JP2025510606A5/ja
Publication of JPWO2023186015A5 publication Critical patent/JPWO2023186015A5/ja
Pending legal-status Critical Current

Links

JP2024554214A 2022-03-30 2023-03-30 Ｂ７ｈ４抗体薬物複合体及びその使用 Pending JP2025510606A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210334522 2022-03-30
CN202210334522.X 2022-03-30
PCT/CN2023/085097 WO2023186015A1 (zh) 2022-03-30 2023-03-30 B7h4抗体药物偶联物及其用途

Publications (3)

Publication Number Publication Date
JP2025510606A JP2025510606A (ja) 2025-04-15
JP2025510606A5 JP2025510606A5 (https=) 2026-04-01
JPWO2023186015A5 true JPWO2023186015A5 (https=) 2026-04-01

Family

ID=88199403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554214A Pending JP2025510606A (ja) 2022-03-30 2023-03-30 Ｂ７ｈ４抗体薬物複合体及びその使用

Country Status (13)

Country Link
US (1) US20250032630A1 (https=)
EP (1) EP4501363A1 (https=)
JP (1) JP2025510606A (https=)
KR (1) KR20240163098A (https=)
CN (1) CN118922210A (https=)
AU (1) AU2023245347A1 (https=)
CA (1) CA3245849A1 (https=)
CL (1) CL2024002903A1 (https=)
CO (1) CO2024013243A2 (https=)
IL (1) IL315698A (https=)
MX (1) MX2024011866A (https=)
TW (2) TW202340255A (https=)
WO (1) WO2023186015A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252282A1 (es) * 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2025077814A1 (en) * 2023-10-14 2025-04-17 Shanghai Hansoh Biomedical Company Limited An antibody-drug conjugate treatment of cancer
TW202535883A (zh) * 2023-10-23 2025-09-16 美商翰森生物有限責任公司 配體–細胞毒性藥物偶聯物及其藥物用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗b7-h4抗体药物偶联物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6943760B2 (ja) * 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
EP3753951A4 (en) * 2018-02-11 2022-03-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MX2021014960A (es) * 2019-06-06 2022-03-04 Shanghai Hansoh Biomedical Co Ltd Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
TWI821699B (zh) * 2020-06-30 2023-11-11 大陸商諾納生物（蘇州）有限公司 抗b7h4抗體及其雙抗和應用

Similar Documents

Publication Publication Date Title
US8889130B2 (en) Treatment of osteoarthritis and pain
JP2012522513A5 (https=)
JP2019031565A5 (https=)
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
JP2012522512A5 (https=)
JP2014139173A5 (https=)
RU2011144119A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2021527640A5 (https=)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JPWO2023046202A5 (https=)
JP2025503214A (ja) Ｈｅｒ３抗体－薬物結合体及びその使用
JPWO2022022508A5 (https=)
JPWO2023186015A5 (https=)
JP2018123122A5 (https=)
JP2025015580A5 (https=)
JP2020534326A5 (https=)
WO2023225577A1 (en) Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates
AU2022316425A1 (en) Drug conjugate of eribulin derivative
JPWO2023033129A5 (https=)
JPWO2023143365A5 (https=)
JPWO2019183253A5 (https=)
JPWO2020257289A5 (https=)
JPWO2020092210A5 (https=)
RU2025131232A (ru) Конъюгат антитело анти-cdh6-лекарственное средство и его применение
RU2025113325A (ru) Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака